Neurogene Statistics
Total Valuation
Neurogene has a market cap or net worth of $425.86 million. The enterprise value is $191.81 million.
Important Dates
The last earnings date was Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Neurogene has 15.80 million shares outstanding. The number of shares has increased by 16.48% in one year.
| Current Share Class | 15.80M |
| Shares Outstanding | 15.80M |
| Shares Change (YoY) | +16.48% |
| Shares Change (QoQ) | +1.01% |
| Owned by Insiders (%) | 10.00% |
| Owned by Institutions (%) | 62.66% |
| Float | 6.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.77 |
| P/TBV Ratio | 1.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.08, with a Debt / Equity ratio of 0.04.
| Current Ratio | 13.08 |
| Quick Ratio | 12.90 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -36,879.33 |
Financial Efficiency
Return on equity (ROE) is -37.25% and return on invested capital (ROIC) is -25.13%.
| Return on Equity (ROE) | -37.25% |
| Return on Assets (ROA) | -23.91% |
| Return on Invested Capital (ROIC) | -25.13% |
| Return on Capital Employed (ROCE) | -45.29% |
| Weighted Average Cost of Capital (WACC) | 15.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$752,962 |
| Employee Count | 131 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +38.06% in the last 52 weeks. The beta is 2.08, so Neurogene's price volatility has been higher than the market average.
| Beta (5Y) | 2.08 |
| 52-Week Price Change | +38.06% |
| 50-Day Moving Average | 24.69 |
| 200-Day Moving Average | 22.33 |
| Relative Strength Index (RSI) | 47.15 |
| Average Volume (20 Days) | 155,487 |
Short Selling Information
The latest short interest is 3.72 million, so 23.54% of the outstanding shares have been sold short.
| Short Interest | 3.72M |
| Short Previous Month | 4.01M |
| Short % of Shares Out | 23.54% |
| Short % of Float | 62.02% |
| Short Ratio (days to cover) | 22.60 |
Income Statement
| Revenue | n/a |
| Gross Profit | -82.28M |
| Operating Income | -110.64M |
| Pretax Income | -98.64M |
| Net Income | -98.64M |
| EBITDA | -107.45M |
| EBIT | -110.64M |
| Earnings Per Share (EPS) | -$4.56 |
Full Income StatementBalance Sheet
The company has $243.18 million in cash and $9.13 million in debt, with a net cash position of $234.05 million or $14.81 per share.
| Cash & Cash Equivalents | 243.18M |
| Total Debt | 9.13M |
| Net Cash | 234.05M |
| Net Cash Per Share | $14.81 |
| Equity (Book Value) | 237.78M |
| Book Value Per Share | 15.23 |
| Working Capital | 227.88M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$82.52 million and capital expenditures -$684,000, giving a free cash flow of -$83.20 million.
| Operating Cash Flow | -82.52M |
| Capital Expenditures | -684,000 |
| Depreciation & Amortization | 3.18M |
| Net Borrowing | -52,000 |
| Free Cash Flow | -83.20M |
| FCF Per Share | -$5.27 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Neurogene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.48% |
| Shareholder Yield | -16.48% |
| Earnings Yield | -23.16% |
| FCF Yield | -19.54% |
Analyst Forecast
The average price target for Neurogene is $80.00, which is 196.85% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $80.00 |
| Price Target Difference | 196.85% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
